SAFC’s Verona plant has just been awarded SafeBridge Certification. But what does this mean, and what does the process involve? SafeBridge President and Chief Executive, John Farris, tells all in the following interview with SAFC Live.
Archive for the ‘Bioconjugation’ Category
An In-Depth Interview with SafeBridge President and CEO, John Farris
Friday, November 4th, 2011Stellar Biotechnologies CEO, Frank Oakes, Discusses KLH Technology and Why They Partnered with SAFC
Tuesday, August 9th, 2011As promised, we return with a new perspective on the Stellar Biotechnologies and SAFC partnership. On August 3rd, Stellar announced SAFC as a partner for the supply of keyhole limpet hemocyanin (KLH), an important component of several vaccines that are in development. In this segment, Stellar President and Chief Executive Officer, Frank Oakes, explains how it produces KLH, and why the partnership is good for both companies.
Producing KLH for Vaccine Use: SAFC’s Dave Backer Discusses the Strategic Marketing and Sales Agreement With Stellar Biotechnologies
Wednesday, August 3rd, 2011
Dave Backer, SAFC Director Marketing and Business Development
SAFC recently signed a deal with California Company Stellar Biotechnologies to provide a reliable source of keyhole limpet hemocyanin, or KLH, extracted from aquacultured limpets. Dave Backer, Director of Marketing and Business Development at SAFC in Carlsbad, explains the background to the deal, and what SAFC is doing with the KLH supplied by Stellar.
BREAKING NEWS: Strategic Agreement Announced Between Pfēnex and SAFC
Tuesday, June 7th, 2011Today, Pfēnex, Inc. announced a non-exclusive partnership with SAFC, under which Pfēnex will support the engineering of strains and processes for SAFC’s biopharmaceutical fermentation business, strengthening capabilities in the areas of microbial strain engineering and the production of complex protein therapeutics and bioconjugation. By pairing Pfēnex’s cutting edge expression technology with the broad range of ingredients and world-class CMO services and facilities of SAFC, the partnership aims to facilitate more comprehensive and time sensitive vaccine development and production for clinical phase trials; both companies are excited about the expansion of capabilities through working together.
A follow up interview with Bill Taylor, Director, Business Development & Commercial Operations of Pfēnex will be available later this week. And next week, an interview with Mark Cassidy, VP of SAFC will go live. These interviews will cover more in-depth detail of this partnership and the benefits it will provide from the perspective of both companies.
